Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01845103 · ClinicalTrials.gov registry record
The PEARL 8.0 Post-Approval Study
A clinical trial, sponsored by Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife.
- Terminated
- Registry status
- 1
- Enrollment target
NCT01845103 is a clinical trial that was terminated before completion, run by Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife. The registered enrollment target is 1 participants.
The verdict
NCT01845103 was terminated before completion, sponsored by Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
This is a prospective single arm study of the Cardiogenesis PEARL 8.0 Handpiece Delivery System. The purpose of this study is to demonstrate that the 30 day mortality rate among patients who are treated with this device is less than the historical rate plus a non-inferiority margin.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2013-09 |
| Est. Completion | 2014-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01845103
The ClinicalTrials.gov registry entry for NCT01845103 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01845103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01845103 about?
NCT01845103 is a clinical study titled "The PEARL 8.0 Post-Approval Study". This is a prospective single arm study of the Cardiogenesis PEARL 8.0 Handpiece Delivery System. The purpose of this study is to demonstrate that the 30 day mortality rate among patients who are treated with this device is less than the historical rate plus a non-inferiority margin.
What is the current status of trial NCT01845103?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2013-09. Estimated completion is 2014-12.
Who is sponsoring clinical trial NCT01845103?
This trial is sponsored by Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.